NCT03276013View on ClinicalTrials.gov

Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

April 30, 2020

Study Completion Date

August 26, 2021

Conditions
Endometrial Neoplasms
Interventions
DRUG

Pembrolizumab

pembrolizumab in combination with doxorubicin

Trial Locations (7)

Unknown

Institut Català d'Oncologia L'Hospitalet (ICO L'Hospitalet), L'Hospitalet de Llobregat

Hospital Universitario Reina Sofía- Córdoba, Córdoba

CUN - Madrid, Madrid

El Centro Integral Oncológico Clara Campal (HM CIOCC),, Madrid

Hospital Universitario La Paz Madrid, Madrid

Hospital Clínico Universitario Lozano Blesa, Zaragoza

08035

Hospital Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Vall d'Hebron Institute of Oncology

OTHER

NCT03276013 - Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer | Biotech Hunter | Biotech Hunter